Eli Lilly & Co.

Oncology and Haematologic Malignancies

Clinical research includes breast cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, pancreatic cancer, ovarian cancer, urothelial carcinoma, thyroid cancer, and other solid tumours, with additional studies in glioma, neuroblastoma, and advanced hematologic malignancies.

  • Metastatic and advanced solid tumours
  • Genomically defined cancers
  • Breast, lung, prostate, and gastrointestinal cancers
  • Brain tumours and paediatric oncology

Research activity also covers tumour subtypes linked to KRAS, RET, FGFR3, IDH1, and IDH2 alterations.

Metabolic, Cardiovascular, and Renal Disorders

Studies focus on type 2 diabetes, type 1 diabetes, obesity, overweight, hypertension, atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, peripheral arterial disease, and chronic kidney disease.

  • Diabetes and beta-cell preservation
  • Weight management and obesity-related disease
  • Cardiovascular risk reduction
  • Kidney function and renal impairment

Additional interest includes lipoprotein(a) and broader lipid disorders in people at elevated cardiovascular risk.

Immunology, Inflammation, and Autoimmune Disease

The sponsor funds trials in rheumatoid arthritis, juvenile idiopathic arthritis, uveitis, atopic dermatitis, alopecia areata, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases.

  • Inflammatory arthritis
  • Skin and hair autoimmune conditions
  • Ocular inflammation
  • Gastrointestinal immune-mediated disease

Research also extends to connective tissue diseases and immune system diseases across adult and paediatric populations.

Neurology, Neurodegeneration, and Migraine

Clinical programmes address Alzheimer disease, dementia, relapsing multiple sclerosis, sporadic amyotrophic lateral sclerosis, chronic migraine, and episodic migraine, alongside broader central nervous system diseases and neurocognitive disorders.

  • Alzheimer’s disease and cognitive decline
  • Multiple sclerosis
  • Motor neuron disease
  • Paediatric and adolescent migraine

Research interest includes disorders affecting the nervous system and neurodegenerative diseases across different stages of life.

Respiratory, Sleep, Pain, and Other Chronic Conditions

Additional studies cover asthma, chronic rhinosinusitis with nasal polyps, obstructive sleep apnea, osteoarthritis, chronic low back pain, neuropathic pain, stress urinary incontinence, nausea, and vomiting.

  • Airway and allergic disease
  • Sleep-disordered breathing
  • Musculoskeletal pain and joint disease
  • Urological symptoms and supportive care

Trial activity also includes chronic pain syndromes and other symptomatic conditions affecting daily function.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Baricitinib and Adalimumab for Children Aged 2 to 17 with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain
  • Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +3
  • Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia France Germany +8
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +4
  • Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Severe Alopecia Areata

    Not yet recruiting

    2 1
    The Netherlands Poland
  • Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

    Not yet recruiting

    2 1
    Belgium Poland